A longitudinal microbiome analysis of glucagon-like peptide-2 (GLP-2) treatment in the patients with short bowel syndrome

This study enrolled five male patients diagnosed with short bowel syndrome (SBS), all of whom had undergone extensive small intestinal resection due to either intestinal volvulus or vascular ischemia, with a remaining jejunal length of 0-40 cm and colon continuity preserved. None of the patients exhibited clinical signs of active inflammatory bowel disease or intestinal motility disorders. All patients received treatment with the GLP-2 analog teduglutide, and fecal samples were collected from the wash solution during enteroscopy at three time points: prior to treatment initiation (0 months), and at 6 and 12 months post-initiation, for the purpose of evaluating longitudinal changes in the intestinal microbiome under GLP-2 therapy.